Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
About Medpace Holdings
Medpace Holdings is a globally recognized clinical research organization (CRO) that specializes in research-based drug development and comprehensive clinical trials. With a robust operational model built on rigorous therapeutic research and strategic partnerships, the company offers tailored solutions to both small and midsize biotechnology firms as well as larger pharmaceutical and medical-device companies. Its emphasis on efficient, cost-effective pathways to drug approval positions Medpace as a trusted steward in every phase of clinical development.
Core Business and Services
At its core, Medpace delivers an all-encompassing suite of services that cover the complete drug development lifecycle. Its offerings range from early-phase trial design and operational management to advanced bioanalytical laboratory services and imaging capabilities. By integrating specialized clinical functions with strategic consultative support, Medpace ensures that each clinical trial is executed with both precision and alacrity. This comprehensive approach helps optimize the clinical trial process, mitigating operational risks and fostering innovation in therapy development.
Operational Excellence and Global Reach
Medpace operates across six continents, harnessing an extensive network of research sites and experienced professionals. This global footprint enables the organization to navigate diverse regulatory environments effectively while maintaining high operational standards. The company’s strategic global engagement not only broadens its service capabilities but also enhances its ability to support multi-regional clinical trials. Its adaptable and flexible business model allows the company to respond to the varied needs of a wide range of sponsors across different market segments.
Strategic Partnerships and Expertise
The company’s success is largely underpinned by its strong strategic partnerships with select sponsors. These partnerships are instrumental in harnessing specialized knowledge, optimizing clinical trial designs, and ensuring regulatory compliance. Medpace leverages its extensive medical and regulatory expertise to provide additional guidance and strategic input across different phases of clinical research. This collaborative approach reinforces its value proposition as a comprehensive CRO that is deeply committed to both scientific excellence and operational integrity.
Industry Position and Significance
Medpace’s positioning within the competitive landscape is marked by its broad service portfolio and deep industry expertise. The company differentiates itself through its methodical approach to clinical research and its long-standing commitment to advancing therapeutic solutions. Unlike many organizations that focus on narrow aspects of clinical research, Medpace offers end-to-end services that seamlessly integrate innovative clinical practices with rigorous regulatory oversight. This integrated service model not only enhances trial efficiency but also contributes to the overall acceleration of life-saving therapies reaching the market.
Commitment to Quality and Efficiency
Quality and efficiency remain the hallmarks of Medpace’s operational strategy. The company continuously refines its methodologies to implement customized solutions that address the unique needs of diverse client groups. Through a combination of advanced research methodologies, state-of-the-art technology, and experienced clinical teams, Medpace ensures that each trial is managed with unparalleled precision and adherence to high-quality standards. This commitment underscores its reputation as a reliable partner in the realm of drug development.
Comprehensive Service Offerings
Medpace provides a range of services that are instrumental in every ensuring phase of clinical development. Highlights include:
- Clinical Trial Management: Comprehensive oversight of trial design, conduct, and monitoring.
- Regulatory Expertise: Guidance and strategies to navigate complex regulatory frameworks.
- Bioanalytical and Imaging Services: Support services that enhance data quality and trial efficiency.
- Consultative Support: Tailored strategies to optimize clinical outcomes and trial execution.
Through these detailed service lines, Medpace continues to fortify its position as a pivotal enabler of research-based drug development, ensuring that sponsors receive precise and informed support throughout the clinical trial process.
Medpace Holdings (MEDP) reported Q1 2025 financial results with revenue reaching $558.6 million, a 9.3% increase from $511.0 million in the prior year. GAAP net income rose to $114.6 million ($3.67 per diluted share), up from $102.6 million ($3.20 per diluted share) year-over-year.
The company's backlog decreased 2.1% to $2.85 billion, with net new business awards of $500.0 million resulting in a book-to-bill ratio of 0.90x. EBITDA grew 2.6% to $118.6 million with a 21.2% margin.
During Q1, Medpace repurchased 1.19 million shares for $389.8 million and received board approval for an additional $1.0 billion share repurchase program. The company projects 2025 revenue between $2.14-2.24 billion, representing 1.5-6.2% growth, with GAAP net income forecast at $378.0-402.0 million.
Medpace Holdings (Nasdaq: MEDP) has announced it will release its first quarter 2025 financial results after market close on Monday, April 21, 2025. The company will hold a conference call to discuss these results on Tuesday, April 22, 2025, at 9:00 a.m. ET.
Participants must pre-register through a provided link to join the conference call. A unique PIN and dial-in number will be provided upon registration. It is recommended to join 10 minutes before the event start. The webcast will be available in the 'Investors' section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will also be available prior to the call.
Medpace Holdings (MEDP) reported Q4 2024 financial results with revenue increasing 7.7% to $536.6 million. Net new business awards were $529.7 million, representing a net book-to-bill ratio of 0.99x. GAAP net income rose significantly to $117.0 million ($3.67 per diluted share), with a net income margin of 21.8%.
For full-year 2024, revenue grew 11.8% to $2,109.1 million, with net new business awards of $2,230.0 million and a book-to-bill ratio of 1.06x. The company's backlog increased 3.2% to $2,902.2 million. EBITDA increased 32.5% to $480.2 million.
Looking ahead, Medpace provided 2025 guidance projecting revenue between $2.110-2.210 billion and GAAP net income of $378.0-402.0 million. The company also announced a $600 million increase to its stock repurchase program.
Medpace Holdings (MEDP) has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on Monday, February 10, 2025. The company will host a conference call on Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss the results.
Participants must pre-register through a provided link to join the conference call. A webcast of the call will be available in the 'Investors' section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will also be available on the website before the call begins.
Medpace Holdings, Inc. (MEDP) reported strong financial results for Q3 2024. Revenue increased 8.3% to $533.3 million, with a backlog conversion rate of 18.2%. GAAP net income rose to $96.4 million, or $3.01 per diluted share, representing a net income margin of 18.1%. EBITDA grew 31.7% to $118.8 million, with an EBITDA margin of 22.3%.
Key highlights include:
- Net new business awards of $533.7 million
- Net book-to-bill ratio of 1.00x
- Backlog increased 8.8% to $2,927.4 million
- Cash and cash equivalents of $656.9 million
For full-year 2024, Medpace forecasts revenue between $2.090 billion and $2.130 billion, representing growth of 10.8% to 12.9% over 2023.
Medpace Holdings, Inc. (Nasdaq: MEDP) has announced that it will release its third quarter 2024 financial results after the market closes on Monday, October 21, 2024. The company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results.
To participate in the conference call, interested parties must register in advance using the provided link. Upon registration, participants will receive a confirmation email with dial-in details and a unique PIN. The company recommends joining 10 minutes before the event start.
A webcast of the call will be available in the "Investors" section of Medpace's website, with a replay accessible approximately one hour after the call ends. Additionally, a supplemental slide presentation will be available on the website prior to the call.
Medpace Holdings, Inc. (MEDP) reported strong financial results for Q2 2024. Revenue increased 14.6% to $528.1 million, with a backlog conversion rate of 18.2%. GAAP net income rose to $88.4 million, or $2.75 per diluted share, up from $61.1 million in Q2 2023. The company's net income margin improved to 16.7%, while EBITDA grew 34.2% to $112.3 million.
Medpace's backlog increased 13.7% to $2,924.9 million, and net new business awards were $551.0 million, resulting in a net book-to-bill ratio of 1.04x. The company updated its 2024 financial guidance, forecasting revenue between $2.125 billion and $2.175 billion, representing 12.7% to 15.3% growth over 2023.
Medpace Holdings will announce its Q2 2024 financial results post-market on July 22, 2024.
A conference call to discuss the results is scheduled for July 23, 2024, at 9:00 a.m. ET.
Participants must register in advance via a provided link, and step-by-step access details will be sent by email.
The call can also be accessed through a webcast on Medpace's investor site, where a replay and supplemental slide presentation will be available post-call.
Medpace is traded under the ticker MEDP on Nasdaq.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
What is the core business of Medpace Holdings?
How does Medpace support the clinical trial process?
What industries does Medpace primarily serve?
How does Medpace ensure regulatory compliance during drug development?
What distinguishes Medpace from other clinical research organizations?
How is Medpace positioned within the global market?
What additional services does Medpace offer beyond clinical trial management?
What role do strategic partnerships play at Medpace?
